Bachem Holding AG stock (CH0012530207): peptide specialist back in focus after recent earnings update

Bachem Holding AG has reported recent quarterly results and updated investors on its peptide and oligonucleotide growth strategy, putting the Swiss small/mid-cap back on the radar of health care and biotech-focused investors.

Bachem Holding AG, a Swiss specialist for active pharmaceutical ingredients based on peptides and oligonucleotides, has recently been in focus again after publishing its latest quarterly figures and business update. The company reported revenue trends and order dynamics that shed light on demand from pharmaceutical and biotech customers, according to a company release and related earnings coverage from early 2025 (Reuters as of 03/14/2025; Bachem investor information as of 03/14/2025).

As of: 22.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Bachem Holding AG
• Sector/industry: Pharmaceuticals, biotech contract manufacturing (CDMO)
• Headquarters/country: Bubendorf, Switzerland
• Core markets: Europe, North America and Asia for branded pharma and biotech clients
• Key revenue drivers: Custom and generic peptide APIs, oligonucleotide development and manufacturing contracts
• Home exchange/listing venue: SIX Swiss Exchange (ticker: BANB)
• Trading currency: Swiss franc (CHF)

Bachem Holding AG: core business model

Bachem focuses on the development and manufacture of peptide and oligonucleotide active pharmaceutical ingredients (APIs) for pharmaceutical and biotechnology companies. The group positions itself as a vertically integrated contract development and manufacturing organization, covering process development, scale-up and commercial production. This positioning targets complex molecules used in modern therapies such as metabolic, oncology and rare disease treatments.

Peptides are short chains of amino acids that act as signaling molecules or therapeutic agents, while oligonucleotides are short nucleic acid sequences used in genetic and RNA-based approaches. Demand for both modalities has grown as drug pipelines shift toward biologics and targeted therapies. Bachem aims to monetize this trend by offering high-quality GMP-compliant manufacturing capacity, which is critical for late-stage clinical trials and commercial launches, according to company descriptions published on its website (Bachem corporate profile as of 11/15/2024).

The business is divided into custom manufacturing, where Bachem produces APIs tailored to individual customer projects, and generic APIs, where it supplies standard peptide products used in established drugs. In recent years the company has also accelerated investments into oligonucleotide capabilities, expanding from traditional peptide strengths into a second high-growth market. This dual focus is designed to diversify revenue streams while leveraging overlapping know-how in complex organic synthesis and purification.

Operationally, Bachem runs multiple production sites in Switzerland, Europe and the United States, supporting global supply chains for major pharmaceutical groups as well as smaller biotechs. The company emphasizes long-term customer relationships, multi-year supply agreements and early involvement in drug development projects, which provide medium-term revenue visibility but also require significant upfront capital expenditure for new capacity and technology platforms.

Main revenue and product drivers for Bachem Holding AG

Revenue at Bachem historically stems from both commercial supply of established peptide drugs and development work for pipeline candidates. Generic APIs generate recurring sales based on mature products, while custom manufacturing revenues are linked to customer project milestones from pre-clinical stages to commercial rollout. This mix means that order intake can be uneven from quarter to quarter, but large contracts can significantly lift medium-term growth, according to past earnings commentary reported in Swiss financial media (Swissinfo earnings coverage as of 03/15/2024).

In the latest published annual and quarterly figures for 2024, Bachem pointed to ongoing investments in capacity for both peptides and oligonucleotides. The company highlighted demand from GLP-1-related peptide projects and from nucleic acid–based therapeutics in development pipelines, while also acknowledging that the ramp-up of new plants and equipment weighed on profitability in the near term, according to its 2024 annual report released in March 2025 (Bachem annual report as of 03/14/2025). For investors, this means that earnings dynamics depend not just on current volumes but also on timing of new project wins and utilization of added capacity.

Beyond production volume, pricing and product mix are important determinants of margins. Complex custom projects and late-stage clinical supplies typically command higher prices and can support attractive gross margins, whereas certain generic APIs are more exposed to competitive pressure. Bachem has repeatedly emphasized quality, regulatory reliability and know-how as factors supporting its pricing power, while still operating in an environment where large pharma buyers closely monitor cost structures and alternative suppliers.

Another driver is the company’s geographic and customer diversification. While Switzerland remains the headquarters, a sizable portion of revenues is tied to U.S. and European pharma clients. The company’s U.S. facilities allow it to serve American customers who prefer domestic or regional manufacturing footprints for critical APIs, which is particularly relevant in light of ongoing discussions around supply chain resilience in the life sciences sector.

Conclusion

Bachem Holding AG sits at the intersection of several important trends in global pharmaceuticals, including the rise of peptide-based medicines and the expansion of oligonucleotide and RNA-related therapies. The company’s recent earnings updates and investment plans underline both the opportunities from growing demand and the financial burden of capacity expansion. For U.S. and international investors following healthcare suppliers and contract manufacturers, Bachem represents an example of a specialized Swiss small/mid-cap with global exposure, meaningful ties to the U.S. market and sensitivity to biotech funding cycles, project timing and regulatory dynamics. Any assessment of the stock therefore needs to balance long-term structural growth drivers with near-term execution and margin risks.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.